导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.21% | 3502/4773 |
| 近一周 | -1.68% | 647/5462 |
| 近一月 | -2.33% | 1243/5421 |
| 近一季 | -5.44% | 1846/5209 |
| 近半年 | -3.71% | 2299/4920 |
| 近一年 | -7.40% | 3223/4366 |
| 近两年 | 39.66% | 1910/2954 |
| 近三年 | 28.61% | 1112/2253 |
| 成立以来 | 14.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.68% 4245/4961 |
7.10% 2752/5312 |
- - |
- - |
| 2025 | 23.08% 1909/4813 |
5.12% 826/3635 |
2.13% 1835/4076 |
18.48% 2296/4524 |
-3.24% 3261/4813 |
| 2024 | 19.61% 512/3463 |
0.20% 1024/2808 |
2.48% 348/3014 |
19.28% 861/3129 |
-2.35% 2050/3463 |
| 2023 | -10.99% 1359/2656 |
1.46% 1567/2280 |
-1.71% 516/2385 |
-5.89% 1391/2515 |
-5.17% 1278/2655 |
| 2022 | -20.83% 995/2207 |
-15.70% 1060/1919 |
5.20% 931/2016 |
-16.95% 1530/2113 |
7.50% 302/2208 |
| 2021 | -10.05% 1091/1822 |
-2.93% 728/1255 |
1.61% 1042/1330 |
-10.01% 1206/1466 |
1.35% 960/1822 |
| 2020 | 25.55% 615/1250 |
-11.85% 857/1028 |
18.26% 346/1067 |
7.38% 787/1164 |
12.16% 498/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 工银湾创100ETF联接C VS. 长安沪深300非周期A(740101) |